Global Molecular Biology Enzymes & Kits & Reagents Market Overview:
According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.
Impact of COVID-19 on the Molecular Biology Enzymes & Kits & Reagents Market
The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Material, By Technique, By Application, By End-Users, By Region
|
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
| Companies Covered | ADS Biotec Inc., Agilent, Aldevron, Bio Basic, Bio-Rad Laboratories, Inc.¸Genekam Biotechnology, Goldsite Diagnostics Inc., Hangzhou Matridx Biotechnology Co. Ltd., Illumina, Integrated DNA Technologies, Inc., Jena Bioscience, LGC Biosearch Technologies, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, New England Biolabs, NZYTech, Promega, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation
|
Driver: increasing number of genome projects
The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.
Restraints: restricted reimbursements for genetic testing
The inflexible reimbursement policy is the restraints to this market.
Opportunity: Research & Development investments offer significant opportunities for the market
Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.
Molecular Biology Enzymes & Kits & Reagents Market Segmentation:
By Product: Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.
By Application: Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.
By End User: Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.
By Region: North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Molecular Biology Enzymes & Kits & Reagents Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Molecular Biology Enzymes & Kits & Reagents Market, By Product, 2019-2030 (USD Million)
6.1. Kits & Reagents
6.2. Enzymes
6.3. Polymerases
6.4. Ligases
6.5. Restriction Endonucleases
6.6. Reverse Transcriptases
6.7. Other Enzymes
7. Molecular Biology Enzymes & Kits & Reagents Market, By Application, 2019-2030 (USD Million)
7.1. PCR
7.2. Sequencing
7.3. Cloning
7.4. Epigenetics
7.5. Restriction Digestion
7.6. Synthetic Biology
7.7. Other Applications
8. Molecular Biology Enzymes & Kits & Reagents Market, By End User, 2019-2030 (USD Million)
8.1. Academic & Research Institutes
8.2. Pharmaceutical & Biotechnology companies
8.3. Hospitals & Diagnostic Centers
8.4. Other End Users
9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. ADS Biotec Inc.
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Agilent
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Aldevron
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Bio Basic
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Bio-Rad Laboratories Inc.
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Genekam Biotechnology
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Goldsite Diagnostics Inc.
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Hangzhou Matridx Biotechnology Co. Ltd.
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Illumina
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Integrated DNA Technologies, Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Jena Bioscience
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. LGC Biosearch Technologies
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Lucigen Corporation
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Merck
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. MoBiTec GmbH
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Molecular Biology Resources
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. New England Biolabs
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. NZYTech
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Promega
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. QIAGEN
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Randox
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Roche
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Takara Bio
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. Thermo Fisher
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
10.25. Zymo Research Corporation
10.25.1. Company details
10.25.2. Financial outlook
10.25.3. Product summary
10.25.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
